Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial

MT Newswires Live08-04 17:42

Nurix Therapeutics (NRIX) said Tuesday it enrolled the first participant in a Phase 3 clinical trial testing its experimental drug bexobrutideg as a treatment for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The global study will compare bexobrutideg with the investigator's choice of pirtobrutinib or idelalisib plus rituximab in approximately 620 patients whose disease progressed after prior treatment with a Bruton's tyrosine kinase inhibitor and a BCL-2 inhibitor, the company said.

Nurix said the trial's co-primary endpoints are overall response rate and progression-free survival, with overall survival among the key secondary endpoints.

The company said the study is intended to support potential regulatory approval of bexobrutideg if successful.

Shares of the company were up 2.3% in Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656572531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 17:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656572531","market":"sg","top_or_hot":-1,"title":"Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> (NRIX) said Tuesday it enrolled the first participant in a Phase 3 clinical trial testing its experimental drug bexobrutideg as a treatment for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.</p><p>The global study will compare bexobrutideg with the investigator's choice of pirtobrutinib or idelalisib plus rituximab in approximately 620 patients whose disease progressed after prior treatment with a Bruton's tyrosine kinase inhibitor and a BCL-2 inhibitor, the company said.</p><p>Nurix said the trial's co-primary endpoints are overall response rate and progression-free survival, with overall survival among the key secondary endpoints.</p><p>The company said the study is intended to support potential regulatory approval of bexobrutideg if successful.</p><p>Shares of the company were up 2.3% in Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-04 17:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> (NRIX) said Tuesday it enrolled the first participant in a Phase 3 clinical trial testing its experimental drug bexobrutideg as a treatment for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.</p><p>The global study will compare bexobrutideg with the investigator's choice of pirtobrutinib or idelalisib plus rituximab in approximately 620 patients whose disease progressed after prior treatment with a Bruton's tyrosine kinase inhibitor and a BCL-2 inhibitor, the company said.</p><p>Nurix said the trial's co-primary endpoints are overall response rate and progression-free survival, with overall survival among the key secondary endpoints.</p><p>The company said the study is intended to support potential regulatory approval of bexobrutideg if successful.</p><p>Shares of the company were up 2.3% in Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656572531","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656572531","pubTimestamp":1785836547,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nurix Therapeutics  said Tuesday it enrolled the first participant in a Phase 3 clinical trial testing its experimental drug bexobrutideg as a treatment for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.The global study will compare bexobrutideg with the investigator's choice of pirtobrutinib or idelalisib plus rituximab in approximately 620 patients whose disease progressed after prior treatment with a Bruton's tyrosine kinase inhibitor and a BCL-2 inhibitor, the company said.Nurix said the trial's co-primary endpoints are overall response rate and progression-free survival, with overall survival among the key secondary endpoints.The company said the study is intended to support potential regulatory approval of bexobrutideg if successful.Shares of the company were up 2.3% in Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRIX":"Nurix Therapeutics"},"translate_title":"Nurix Therapeutics 招募首位患者参与 3 期血癌试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1.5},"content_text":"Nurix Therapeutics (NRIX) said Tuesday it enrolled the first participant in a Phase 3 clinical trial testing its experimental drug bexobrutideg as a treatment for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.The global study will compare bexobrutideg with the investigator's choice of pirtobrutinib or idelalisib plus rituximab in approximately 620 patients whose disease progressed after prior treatment with a Bruton's tyrosine kinase inhibitor and a BCL-2 inhibitor, the company said.Nurix said the trial's co-primary endpoints are overall response rate and progression-free survival, with overall survival among the key secondary endpoints.The company said the study is intended to support potential regulatory approval of bexobrutideg if successful.Shares of the company were up 2.3% in Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656572531","isCrawlerRequest":true}